Strategic Investment Advisors MI Sells 346 Shares of Johnson & Johnson (NYSE:JNJ)

Strategic Investment Advisors MI decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.4% during the first quarter, HoldingsChannel reports. The fund owned 3,340 shares of the company’s stock after selling 346 shares during the quarter. Strategic Investment Advisors MI’s holdings in Johnson & Johnson were worth $554,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Lantz Financial LLC raised its position in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after purchasing an additional 377 shares during the period. Sulzberger Capital Advisors Inc. bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $453,000. Horan Securities Inc. raised its holdings in shares of Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after buying an additional 90 shares during the period. State of Wyoming lifted its stake in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after acquiring an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC boosted its holdings in Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock valued at $2,635,000 after acquiring an additional 2,529 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.1%

Johnson & Johnson stock opened at $152.33 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm has a market cap of $366.52 billion, a P/E ratio of 16.94, a P/E/G ratio of 2.31 and a beta of 0.42. The business has a fifty day moving average of $153.95 and a two-hundred day moving average of $153.67. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent analyst reports. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 16th. Finally, Leerink Partnrs downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.